DNAPrint Operating Margin from 2010 to 2026
DNAPrint Genomics' Operating Profit Margin is decreasing over the last several years with slightly volatile swings. Operating Profit Margin is estimated to finish at -3.98 this year.
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
DNAPrint | Operating Margin | Build AI portfolio with DNAPrint Stock |
Latest DNAPrint Genomics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of DNAPrint Genomics over the last few years. It is DNAPrint Genomics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DNAPrint Genomics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.31) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
DNAPrint Operating Margin Regression Statistics
| Arithmetic Mean | 6.95 | |
| Geometric Mean | 4.64 | |
| Coefficient Of Variation | 631.81 | |
| Mean Deviation | 20.05 | |
| Median | (3.64) | |
| Standard Deviation | 43.91 | |
| Sample Variance | 1,928 | |
| Range | 182 | |
| R-Value | (0.41) | |
| Mean Square Error | 1,711 | |
| R-Squared | 0.17 | |
| Significance | 0.10 | |
| Slope | (3.56) | |
| Total Sum of Squares | 30,846 |
DNAPrint Operating Margin History
About DNAPrint Genomics Financial Statements
DNAPrint Genomics stakeholders use historical fundamental indicators, such as DNAPrint Genomics' Operating Margin, to determine how well the company is positioned to perform in the future. Although DNAPrint Genomics investors may analyze each financial statement separately, they are all interrelated. For example, changes in DNAPrint Genomics' assets and liabilities are reflected in the revenues and expenses on DNAPrint Genomics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DNAPrint Genomics. Please read more on our technical analysis and fundamental analysis pages.
DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany. DNAPRINT GENOMICS is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
When determining whether DNAPrint Genomics is a strong investment it is important to analyze DNAPrint Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DNAPrint Genomics' future performance. For an informed investment choice regarding DNAPrint Stock, refer to the following important reports:Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DNAPrint Genomics. If investors know DNAPrint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DNAPrint Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DNAPrint Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DNAPrint Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNAPrint Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.